Comparative Pharmacology
Head-to-head clinical analysis: DARVON N versus NORCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON N versus NORCET.
DARVON-N vs NORCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist that produces analgesia by binding to opioid receptors in the central nervous system, altering the perception of and response to pain. Its metabolite norpropoxyphene has local anesthetic and sodium channel blocking effects, which may contribute to cardiac toxicity.
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
100 mg orally every 4 hours as needed for pain; maximum 600 mg per day.
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours. Accumulation of norpropoxyphene on repeated dosing increases risk of toxicity.
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugates); minor biliary/fecal elimination (25-30%).
Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic